These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8973689)

  • 1. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
    Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
    Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.
    O'Donnell MA; Krohn J; DeWolf WC
    J Urol; 2001 Oct; 166(4):1300-4, discussion 1304-5. PubMed ID: 11547062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
    Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
    Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical immunotherapy for superficial bladder cancer.
    Said MT; Abomelha MS; Orkubi SA
    Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
    Liu W; O'Donnell MA; Chen X; Han R; Luo Y
    Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
    Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
    J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder.
    Bazarbashi S; Soudy H; Abdelsalam M; Al-Jubran A; Akhtar S; Memon M; Aslam M; Kattan S; Shoukri M
    BJU Int; 2011 Oct; 108(7):1115-8. PubMed ID: 21332904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
    Luciani LG; Neulander E; Murphy WM; Wajsman Z
    Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
    Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
    J Urol; 2010 Nov; 184(5):1920-4. PubMed ID: 20846678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy.
    Punnen SP; Chin JL; Jewett MA
    Can J Urol; 2003 Apr; 10(2):1790-5. PubMed ID: 12773228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
    Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
    Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer.
    O'Donnell MA; Lilli K; Leopold C;
    J Urol; 2004 Sep; 172(3):888-93. PubMed ID: 15310991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
    Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
    Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder.
    Saxena S; Agrawal U; Agarwal A; Murthy NS; Mohanty NK
    BJU Int; 2006 Nov; 98(5):1012-7. PubMed ID: 17034604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.